Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP546C in CLDN18.2-expressing Solid Tumors
NCT07488676Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- May 2026
- Primary completion
- Jul 2029
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of ASP546C in gastroesophageal adenocarcinoma, pancreatic adenocarcinoma (PDAC), solid tumor, sponsored by Astellas Pharma. Started May 2026; status: recruiting.
02
Drugs
ASP546C
03
Conditions
gastroesophageal adenocarcinomapancreatic adenocarcinoma (PDAC)solid tumor
Beyond the preview
Go deeper on NCT07488676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07488676.